Gitterman Wealth Management LLC Sells 2,205 Shares of Johnson & Johnson (NYSE:JNJ)

Gitterman Wealth Management LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJFree Report) by 11.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,644 shares of the company’s stock after selling 2,205 shares during the period. Johnson & Johnson comprises 1.2% of Gitterman Wealth Management LLC’s investment portfolio, making the stock its 6th biggest position. Gitterman Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,592,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of JNJ. Hibernia Wealth Partners LLC purchased a new stake in Johnson & Johnson during the 3rd quarter worth about $27,000. FNY Investment Advisers LLC purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at about $37,000. Tower View Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 183.3% in the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after acquiring an additional 165 shares during the last quarter. Creative Capital Management Investments LLC increased its holdings in shares of Johnson & Johnson by 43.0% in the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock valued at $45,000 after acquiring an additional 86 shares during the last quarter. Finally, VitalStone Financial LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter valued at about $48,000. Hedge funds and other institutional investors own 68.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on JNJ shares. Raymond James increased their price objective on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. TheStreet downgraded Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, November 17th. UBS Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price objective for the company from $167.00 to $180.00 in a report on Friday, December 1st. Barclays raised their price target on Johnson & Johnson from $158.00 to $162.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 12th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Eight equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Hold” and a consensus target price of $167.87.

Check Out Our Latest Report on JNJ

Johnson & Johnson Stock Performance

Shares of JNJ opened at $158.76 on Wednesday. The company’s 50 day simple moving average is $157.47 and its 200 day simple moving average is $159.25. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21. The company has a market capitalization of $382.18 billion, a price-to-earnings ratio of 11.50, a PEG ratio of 2.68 and a beta of 0.53. Johnson & Johnson has a 1 year low of $144.95 and a 1 year high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating the consensus estimate of $2.28 by $0.01. The firm had revenue of $21.40 billion during the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. The business’s quarterly revenue was down 9.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.35 earnings per share. On average, sell-side analysts predict that Johnson & Johnson will post 10.67 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be paid a $1.19 dividend. The ex-dividend date is Friday, February 16th. This represents a $4.76 annualized dividend and a yield of 3.00%. Johnson & Johnson’s payout ratio is currently 34.47%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.